Pashtoon Murtaza Kasi MD

Oncology•Irvine, CA

Cancer Genetics/Cancer Risk Assessment, Gastrointestinal Cancer, Hematologic Oncology

Oncology, Gastrointestinal Malignancies (Colon & Rectal Cancer; Hereditary GI Cancers, BRCA 1/2)

Join to View Full Profile

1000 FivepointIrvine, CA 92618
Phone+1 800-826-4673

Summary

Associate Professor Oncology,
Post-Doctoral Master’s in Basic and Biomedical Sciences.

Clinical Expertise

Immunotherapy, Biological Therapy, Medical oncology, Hematology, Toll-Like Receptor 4, Tumor Cell Line, Combined modality therapy, Adjuvant chemotherapy, Gastrointestinal / Hepatic pathology, Colonic neoplasms, Cholangiocarcinoma, Pancreatic Neoplasms, BRCA2 Genes, BRCA1 Genes, Gastrointestinal oncology, Hematologic oncology, Colon cancer, Liver metastases, Metastatic diseases, Hepatic metastases, Metastatic colon cancer, Colorectal cancer, Hereditary nonpolyposis colorectal cancer, General medical oncology, Pancreatic cancer, Hepatic cancer

Education & Training

Mayo School of Graduate Medical EducationM.S., Basic and Biomedical Sciences , 2015 - 2018
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2013 - 2016
UPMC Medical EducationResidency, Internal Medicine, 2010 - 2013
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineInternship, Transitional Year, 2009 - 2010
Aga Khan Medical CollegeClass of 2006

Certifications & Licensure

IA State Medical License 2019 - 2027
NJ State Medical License 2024 - 2027
NY State Medical License 2021 - 2027
CA State Medical License 2024 - 2026
FL State Medical License 2016 - 2026
MN State Medical License 2013 - 2026
PA State Medical License 2010 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Teamwork - Above and Beyond Recognition Program Mayo Clinic, 2017
Excellence - Above and Beyond Recognition Program Mayo Clinic, 2017
Tow Tan Humanism in Medicine Mayo Clinic, 2016
Outstanding Hematology-Oncology Fellowship Trainee Mayo Clinic, 2016
Excellence in Patient Care and Professionalism - Nominee Mayo Clinic, 2015-2016
Humanism and Excellence in Teaching Arnold P. Gold Foundation, 2012
Join now to see all

Clinical Trials

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2016 May 20
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Approved for marketing
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer Start of enrollment: 2016 Sep 01
ACTIVE_NOT_RECRUITING
PHASE2
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer Start of enrollment: 2017 Jan 11
Completed
Phase 2
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer Start of enrollment: 2016 Oct 13
Completed
Phase 3
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer Start of enrollment: 2016 Nov 29
Completed
Phase 2
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) Start of enrollment: 2018 Feb 23
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results.
Zev A Wainberg, Colin D Weekes, Muhammad Furqan, Pashtoon M Kasi, Craig E Devoe
Nature Medicine. 2025-08-11
Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma.
Michael S Lee, Joseph Chao, Mary F Mulcahy, Pashtoon M Kasi, Angela T Alistar
The Oncologist. 2025-07-04
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes.
Sriram Anbil, Nicholas J Seewald, E Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi
JCO Precision Oncology. 2025-07-01

Journal Articles

Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
Pashtoon M Kasi, Robert R McWilliams, JAMA

Lectures

A phase II trial of pharmacological ascorbate, gemcitabine, and nabpaclitaxel for metastatic pancreatic cancer.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer.
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Circulating tumor DNA dynamics, serial testing and evolution on treatment in 322 colorectal cancer patients.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Incidence of pathogenic variants in individuals with a personal or family history of pancreatic cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Press Mentions

Immunotherapy Drug Eliminated Need for Surgery, Chemo in Early Stage CancersMay 2nd, 2025
Common Pain Medication Could Reduce Cancer Spread, Study FindsMarch 12th, 2025
Common Cancer Type Could Be Detected with New Blood TestFebruary 4th, 2025
Join now to see all

Grant Support

BRCA-Related Pancreatic Cancer: Outcomes and PD-L1 expressionMayo Clinic Cancer Center2017–2019